{"id":522029,"date":"2021-08-03T08:03:24","date_gmt":"2021-08-03T12:03:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/silverback-therapeutics-to-participate-in-the-2021-wedbush-pacgrow-healthcare-conference\/"},"modified":"2021-08-03T08:03:24","modified_gmt":"2021-08-03T12:03:24","slug":"silverback-therapeutics-to-participate-in-the-2021-wedbush-pacgrow-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/silverback-therapeutics-to-participate-in-the-2021-wedbush-pacgrow-healthcare-conference\/","title":{"rendered":"Silverback Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference"},"content":{"rendered":"

<\/p>\n

Silverback Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference<\/b><\/p>\n

SEATTLE–(BUSINESS WIRE<\/a>)–
\nSilverback Therapeutics, Inc. (Nasdaq: SBTX) (\u201cSilverback\u201d), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced that the Company will participate in the 2021 Wedbush PacGrow Healthcare Conference from August 10-11, 2021.\n<\/p>\n

\nLaura Shawver, Ph.D., Silverback\u2019s Chief Executive Officer, will participate in the \u201cHeavenly (anti)Bodies\u201d panel on Tuesday, August 10, 2021 at 1:10 p.m. ET (10:10 a.m. PT). Members of the Silverback management team will also host investor meetings during the conference.\n<\/p>\n

About Silverback Therapeutics <\/b><\/p>\n

\nSilverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Silverback\u2019s platform enables the strategic pairing of proprietary payloads that modulate key disease modifying pathways with monoclonal antibodies directed at specific disease sites. Initially, Silverback is creating a new class of targeted immuno-oncology agents that direct a TLR8 agonist myeloid cell activator to the tumor microenvironment in solid tumors to promote cancer cell killing. Silverback Therapeutics is located in Seattle, Washington. To learn more, visit www.silverbacktx.com<\/a>.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210803005026\/en\/<\/a><\/span><\/p>\n

Investor Contact:
\n<\/i>
Miguel Arcinas
\n
Silverback Therapeutics
\n
(206) 736-7946
\n
ir@silverbacktx.com<\/a><\/p>\n

Media Contact:
\n<\/i>
Jason Spark
\n
Canale Communications
\n
(619) 849-6005
\n
jason.spark@canalecomm.com<\/a><\/p>\n

\n\u00a0\n<\/p>\n

KEYWORDS:<\/b> United States North America Washington<\/p>\n

INDUSTRY KEYWORDS:<\/b> Oncology Health Infectious Diseases Research Science Pharmaceutical Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Silverback Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference SEATTLE–(BUSINESS WIRE)– Silverback Therapeutics, Inc. (Nasdaq: SBTX) (\u201cSilverback\u201d), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced that the Company will participate in the 2021 Wedbush PacGrow Healthcare Conference from August 10-11, 2021. Laura Shawver, Ph.D., Silverback\u2019s Chief Executive Officer, will participate in the \u201cHeavenly (anti)Bodies\u201d panel on Tuesday, August 10, 2021 at 1:10 p.m. ET (10:10 a.m. PT). Members of the Silverback management team will also host investor meetings during the conference. About Silverback Therapeutics Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on leveraging … <\/p>\n

Continue reading “Silverback Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-522029","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSilverback Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/silverback-therapeutics-to-participate-in-the-2021-wedbush-pacgrow-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Silverback Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Silverback Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference SEATTLE–(BUSINESS WIRE)– Silverback Therapeutics, Inc. (Nasdaq: SBTX) (\u201cSilverback\u201d), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced that the Company will participate in the 2021 Wedbush PacGrow Healthcare Conference from August 10-11, 2021. Laura Shawver, Ph.D., Silverback\u2019s Chief Executive Officer, will participate in the \u201cHeavenly (anti)Bodies\u201d panel on Tuesday, August 10, 2021 at 1:10 p.m. ET (10:10 a.m. PT). Members of the Silverback management team will also host investor meetings during the conference. About Silverback Therapeutics Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on leveraging … Continue reading "Silverback Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/silverback-therapeutics-to-participate-in-the-2021-wedbush-pacgrow-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-03T12:03:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210803005026r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silverback-therapeutics-to-participate-in-the-2021-wedbush-pacgrow-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silverback-therapeutics-to-participate-in-the-2021-wedbush-pacgrow-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Silverback Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference\",\"datePublished\":\"2021-08-03T12:03:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silverback-therapeutics-to-participate-in-the-2021-wedbush-pacgrow-healthcare-conference\\\/\"},\"wordCount\":276,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silverback-therapeutics-to-participate-in-the-2021-wedbush-pacgrow-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210803005026r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silverback-therapeutics-to-participate-in-the-2021-wedbush-pacgrow-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silverback-therapeutics-to-participate-in-the-2021-wedbush-pacgrow-healthcare-conference\\\/\",\"name\":\"Silverback Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silverback-therapeutics-to-participate-in-the-2021-wedbush-pacgrow-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silverback-therapeutics-to-participate-in-the-2021-wedbush-pacgrow-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210803005026r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-08-03T12:03:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silverback-therapeutics-to-participate-in-the-2021-wedbush-pacgrow-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silverback-therapeutics-to-participate-in-the-2021-wedbush-pacgrow-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silverback-therapeutics-to-participate-in-the-2021-wedbush-pacgrow-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210803005026r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210803005026r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silverback-therapeutics-to-participate-in-the-2021-wedbush-pacgrow-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Silverback Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Silverback Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/silverback-therapeutics-to-participate-in-the-2021-wedbush-pacgrow-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Silverback Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference - Market Newsdesk","og_description":"Silverback Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference SEATTLE–(BUSINESS WIRE)– Silverback Therapeutics, Inc. (Nasdaq: SBTX) (\u201cSilverback\u201d), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced that the Company will participate in the 2021 Wedbush PacGrow Healthcare Conference from August 10-11, 2021. Laura Shawver, Ph.D., Silverback\u2019s Chief Executive Officer, will participate in the \u201cHeavenly (anti)Bodies\u201d panel on Tuesday, August 10, 2021 at 1:10 p.m. ET (10:10 a.m. PT). Members of the Silverback management team will also host investor meetings during the conference. About Silverback Therapeutics Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on leveraging … Continue reading \"Silverback Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/silverback-therapeutics-to-participate-in-the-2021-wedbush-pacgrow-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-03T12:03:24+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210803005026r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silverback-therapeutics-to-participate-in-the-2021-wedbush-pacgrow-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silverback-therapeutics-to-participate-in-the-2021-wedbush-pacgrow-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Silverback Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference","datePublished":"2021-08-03T12:03:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silverback-therapeutics-to-participate-in-the-2021-wedbush-pacgrow-healthcare-conference\/"},"wordCount":276,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silverback-therapeutics-to-participate-in-the-2021-wedbush-pacgrow-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210803005026r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silverback-therapeutics-to-participate-in-the-2021-wedbush-pacgrow-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/silverback-therapeutics-to-participate-in-the-2021-wedbush-pacgrow-healthcare-conference\/","name":"Silverback Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silverback-therapeutics-to-participate-in-the-2021-wedbush-pacgrow-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silverback-therapeutics-to-participate-in-the-2021-wedbush-pacgrow-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210803005026r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-08-03T12:03:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silverback-therapeutics-to-participate-in-the-2021-wedbush-pacgrow-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/silverback-therapeutics-to-participate-in-the-2021-wedbush-pacgrow-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silverback-therapeutics-to-participate-in-the-2021-wedbush-pacgrow-healthcare-conference\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210803005026r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210803005026r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silverback-therapeutics-to-participate-in-the-2021-wedbush-pacgrow-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Silverback Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/522029","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=522029"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/522029\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=522029"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=522029"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=522029"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}